Clinical Trial: Alpaglitovirizumab (QL1706) combined with chemotherapy for late stage treatment A single arm, open, multicenter neoadjuvant therapy for endometrial cancer Phase II clinical study (China)

Posted On: 2026-09-14

China, Sept. 14 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Alpaglitovirizumab (QL1706) combined with chemotherapy for late stage treatment A single arm, open, multicenter neoadjuvant therapy for endometrial cancer Phase II clinical study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132330

Registration Time: 2026/09/11

Type: Interventional study

Primary Sponsor: Fujian Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339670

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Alpaglitovirizumab (QL1706) combined with chemotherapy for late stage treatment A single arm, open, multicenter neoadjuvant therapy for endometrial cancer Phase II clinical study (China)